226 / 1138
Teaching goals
Understand comparative effectiveness research (CER), and how it
led to SBRT becoming a guideline-recommended standard of care.
Know why aging populations and comorbidity are both likely to lead
to SBRT being used in operable patients with Stage I NSCLC.
Understand why advances in systemic therapy will lead to increasing
clinical demands for SBRT in metastatic disease.
Be aware of the focus on ‘
value
’ in healthcare, and the role of patient
reported outcomes, in determining reimbursements.